Study of Moxetumomab Pasudotox in pALL or LL of B-Cell Origin

• Research type

  Research Study

• Full title

  A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin

• IRAS ID

  116688

• Contact name

  Francis Mussai

• Contact email

  francis.mussai@bch.nhs.uk

• Sponsor organisation

  MedImmune, LLC, a wholly owned subsidiary of AstraZeneca,

• Eudract number

  2012-003101-10

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• REC name

  West Midlands - Coventry & Warwickshire Research Ethics Committee

• REC reference

  13/WM/0143

• Date of REC Opinion

  3 May 2013

• REC opinion

  Favourable Opinion